

RECEIVED
CENTRAL FAX CENTER

AUG 20 2007

SCHWEGMAN ■ LUNDBERG ■ WOESSNER
PATENT, TRADEMARK & COPYRIGHT ATTORNEYS
P.O. Box 2938
Minneapolis, MN 55402
Telephone (612) 373-6900 Facsimile (612) 339-3061

August 20, 2007

TO: Commissioner for Patents
Attn: U. Ramachandran
Patent Examining Corps
Facsimile Center
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Janet E. EmbretsonOUR REF: 295.009US4FAX NUMBER (571) 273-8300

* Please deliver to Examiner U. Ramachandran in Art Unit 1617. *


Document(s) Transmitted: Revocation and Power of Attorney & Change of Correspondence
Address (1 pg.).

Total pages of this transmission, including cover letter: 2 pgs.


If you do NOT receive all of the pages described above, please telephone us at 612-373-6900 or fax us at 612-339-3061.

In re. Patent Application of: David J. Grainger et alExaminer: U. RamachandranSerial No.: 10/729,056Group Art Unit: 1617Filed: December 5, 2003Docket No.: 295.009US4

Title: PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH
TAMOXIFEN ANALOGUES

By: 
Name: Janet E. Embretson
Reg. No.: 39,665

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.


Michele Quaranto

8-20-2007
Date of Transmission

RECEIVED
CENTRAL FAX CENTER

AUG 20 2007

S/N 10/729,056PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	David J. Grainger et al.	Examiner:	Jennifer M. Kim
Serial No.:	10/729,056	Group Art Unit:	1617
Filed:	December 5, 2003	Docket:	295.009US4
Title:	PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES		

REVOCATION AND POWER OF ATTORNEY
CERTIFICATE UNDER 37 CFR § 3.73(b)

&

CHANGE OF CORRESPONDENCE ADDRESS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 C.F.R. Section 1.36, M.P.E.P. Section 402.05 and 402.07, please revoke any existing Powers of Attorney, if any, and appoint the following attorneys and/or patent agents to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith:

Customer Number: 45837

CERTIFICATE UNDER 37 CFR § 3.73(b)

Poniard Pharmaceuticals, Inc. hereby certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of the following:

an assignment from the inventors to NeoRx filed 10/26/2006 and recorded on Reel 018453, Frames 0263 - 0267; and,

a Change of Name from NeoRx to Poniard Pharmaceuticals, Inc. filed 08/07/2007 and recorded on Reel 019658, Frames 0565 - 0569. To the best of my knowledge and belief, title is in Poniard Pharmaceuticals, Inc., the assignee.

Pursuant to 37 C.F.R. §3.73(b) I hereby declare that I am empowered to sign this certificate on behalf of Poniard Pharmaceuticals, Inc., the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true.

Please direct all correspondence in this case to:


Schwegman, Lundberg, Woessner & Kluth, P.A.
Customer No. 45837

Date 8/17/07

By

Name:

Title:


ANNA LEWAK WIGHT
Vice President Legal